Business Wire

TAKEDA-PHARMACEUTICAL

27.1.2021 11:02:10 CET | Business Wire | Press release

Share
Takeda Achieved Carbon Neutrality in 2020

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it achieved carbon neutrality in its value chain for its fiscal year 2019. This achievement was delivered by a continued focus on internal energy conservation measures, procurement of green energy, and investment in renewable energy certificates and high-quality, verified carbon offsets. These actions collectively address 100 percent of Takeda’s fiscal year 2019 scope 1, 2, and 3 emissions1 and represent a significant milestone in Takeda’s sustainability journey.

“This important milestone underscores our commitment to environmental sustainability as we recognize that climate change poses a risk to human health, including the spread of some of the same infectious diseases we’re working to eradicate,” said Christophe Weber, Takeda president and chief executive officer. “As a global, purpose-driven company celebrating our 240-year anniversary this summer, I am proud of our achievement, but we know much more work needs to be done. We remain committed to using our size and scale to help mitigate climate change and to ensure we can continue to make a positive impact on patients, our people and the planet.”

One of the ways Takeda achieved this milestone is through its investment in more than 30 renewable energy and carbon offset projects across 12 countries. These projects support the use of wind and solar energy, clean water availability, forest conservation and the preservation of biodiversity. The activities collectively address 15 out of 17 of the United Nations’ Sustainable Development Goals. They support local communities, while promoting a more sustainable future. All carbon offsets were required to meet rigorous evaluation criteria, including additionality, measurability, transparency, registration and third-party verification, among others.

Projects supported include:

  • Clean drinking water in Malawi – providing safe drinking water to communities by creating new boreholes and repairing damaged ones, resulting in the reduced use of firewood for boiling and purifying water
  • Working Woodlands Program – preserving more than 8,600 acres in the northeastern corner of Tennessee, U.S., as a privately held park, encouraging recreation-based tourism in a lower-income region of the United States
  • Forest management in Japan – supporting natural carbon sinks and local air quality through sustainable forestry management practices in Japan
  • Solar cookstoves in China – helping to improve indoor air quality by investing in the installation of solar cookers to replace coal for cooking and hot water needs for rural farmers in remote areas of China
  • Solar energy in India – supporting the development of solar lighting and thermal water heating to replace fossil fuel usage throughout different states in India

Building on today’s milestone, Takeda remains committed to eliminating greenhouse gas emissions from its company-wide operations. Specifically, Takeda aims to reduce 40 percent of its emissions from its operations by 2025 and has committed to being carbon zero by 2040. To achieve its climate-related goals, a company-wide, cross-divisional program has been established to increase renewable energy usage and drive energy efficiency. Takeda is also looking beyond its own operations and is working with suppliers to help them to establish science-based reduction targets and reduce greenhouse gas emissions.

As a science-driven organization, Takeda’s climate change commitments are aligned with current climate science. In 2020, the Science-Based Targets initiative (SBTi) recognized Takeda’s goals as being consistent with reductions required to limit the rise in global temperature to 1.5°C above pre-industrial levels. Takeda is also proud to have earned a spot on CDP’s ‘A List’ for climate change leadership in 2020 as well as being named to Corporate Knights Global 100 Most Sustainable Corporations in the World (Global 100) for the sixth consecutive year.

For more information on Takeda’s commitment to environmental sustainability, visit:
Takeda environment website
Sustainability Value Report 2020

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK ) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries. For more information, visit https://www.takeda.com .

1 Scope 1 emissions are direct emissions from owned or controlled sources such as onsite fuel combustion, company-owned vehicles, and in-equipment in our facilities.
Scope 2 emissions are indirect greenhouse gas emissions resulting from purchased and consumed electricity, third party steam and/or chilled water supplied to our facilities.
Scope 3 emissions are all other indirect emissions that occur in our value chain, including goods and services provided by suppliers, business travel, employee commuting, and landfill waste disposal.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release

‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub

Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release

New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki

Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release

90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release

For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye